Damora Therapeutics, Inc.
(DMRA)Financial Statements · SEC EDGAR XBRL
Net Income
-$209.8M
-878.8%
EPS
$3.98
+121.5%
Op. Income
-$210.9M
-847.3%
Source: SEC EDGAR XBRL
Breakdown
Revenues
Operating Expenses & Income
Research & Development
Total Operating Expenses
Operating Income
Non-Operating Income/Expense
Other Non-Operating Income
Pre-Tax Income
Income Tax Expense
Net Income
EPS (Basic)
EPS (Diluted)
Shares Outstanding (Diluted)